Rabbit Anti-PIK3CA Recombinant Antibody (CBYC-P380) (CBMAB-P1798-YC)

Rabbit

Human

CBYC-P380

IgG

IF, IP, WB

Human

IgG

Monoclonal

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

PBS, pH 7.2

Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22.

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide; Serine/Threonine Protein Kinase PIK3CA; PtdIns-3-Kinase Subunit P110-Alpha; PI3K-Alpha; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit, Alpha Isoform; Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Alpha; Phosphatidylinositol 4,5-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Alpha; Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha; Phosphatidylinositol 3-Kinase, Catalytic, Alpha Polypeptide; Phosphatidylinositol 3-Kinase, Catalytic, 110-KD, Alpha; Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide; PI3-Kinase P110 Subunit Alpha; PtdIns-3-Kinase Subunit Alpha;

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:15135396, PubMed:23936502, PubMed:28676499).
Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, PubMed:28676499).
PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. In addition to its lipid kinase activity, it displays a serine-protein kinase activity that results in the autophosphorylation of the p85alpha regulatory subunit as well as phosphorylation of other proteins such as 4EBP1, H-Ras, the IL-3 beta c receptor and possibly others (PubMed:23936502, PubMed:28676499).
Plays a role in the positive regulation of phagocytosis and pinocytosis (By similarity).

Actin cytoskeleton organizationISS:BHF-UCL
Adipose tissue developmentIEA:Ensembl
AngiogenesisIEA:UniProtKB-KW
Anoikis1 PublicationNAS:ParkinsonsUK-UCL
Cardiac muscle cell contractionISS:BHF-UCL
Cardiac muscle contractionManual Assertion Based On ExperimentTAS:UniProtKB
Cell migrationManual Assertion Based On ExperimentIBA:GO_Central
Cellular response to glucose stimulusIEA:Ensembl
Cellular response to hydrostatic pressureBy SimilarityISS:BHF-UCL
Endothelial cell migrationManual Assertion Based On ExperimentTAS:UniProtKB
Energy homeostasisIEA:Ensembl
Epidermal growth factor receptor signaling pathwayTAS:Reactome
Glucose metabolic processIEA:Ensembl
Hypomethylation of CpG islandIEA:Ensembl
Insulin receptor signaling pathway via phosphatidylinositol 3-kinaseManual Assertion Based On ExperimentTAS:UniProtKB
Liver developmentIEA:Ensembl
Negative regulation of actin filament depolymerizationISS:BHF-UCL
Negative regulation of anoikisManual Assertion Based On ExperimentIMP:UniProtKB
Negative regulation of fibroblast apoptotic processIEA:Ensembl
Negative regulation of gene expressionIEA:Ensembl
Negative regulation of macroautophagy1 PublicationNAS:ParkinsonsUK-UCL
Negative regulation of neuron apoptotic processIEA:Ensembl
PhagocytosisIEA:UniProtKB-KW
Phosphatidylinositol 3-kinase signalingManual Assertion Based On ExperimentIGI:BHF-UCL
Phosphatidylinositol phosphate biosynthetic processISS:BHF-UCL
Phosphatidylinositol-3-phosphate biosynthetic processManual Assertion Based On ExperimentIBA:GO_Central
Phosphatidylinositol-mediated signalingManual Assertion Based On ExperimentIBA:GO_Central
PhosphorylationManual Assertion Based On ExperimentIDA:MGI
Platelet activationManual Assertion Based On ExperimentTAS:UniProtKB
Positive regulation of lamellipodium assemblyISS:BHF-UCL
Positive regulation of peptidyl-serine phosphorylationIEA:Ensembl
Positive regulation of protein kinase B signalingManual Assertion Based On ExperimentIGI:BHF-UCL
Positive regulation of smooth muscle cell proliferationIEA:Ensembl
Positive regulation of TOR signaling1 PublicationNAS:ParkinsonsUK-UCL
Protein kinase B signalingIEA:Ensembl
Regulation of actin filament organizationISS:BHF-UCL
Regulation of cellular respirationIEA:Ensembl
Regulation of genetic imprintingIEA:Ensembl
Regulation of multicellular organism growthIEA:Ensembl
Relaxation of cardiac muscleISS:BHF-UCL
Response to activityIEA:Ensembl
Response to butyrateIEA:Ensembl
Response to dexamethasoneIEA:Ensembl
Response to leucineIEA:Ensembl
Response to muscle inactivityIEA:Ensembl
Response to muscle stretchISS:BHF-UCL
T cell costimulationTAS:Reactome
T cell receptor signaling pathwayTAS:Reactome
Vascular endothelial growth factor signaling pathwayManual Assertion Based On ExperimentIGI:BHF-UCL
Vasculature developmentManual Assertion Based On ExperimentTAS:UniProtKB

cytoplasm
cytosol
intercalated disc
lamellipodium
membrane
perinuclear region of cytoplasm
phosphatidylinositol 3-kinase complex
phosphatidylinositol 3-kinase complex, class IA
phosphatidylinositol 3-kinase complex, class IB
plasma membrane

Colorectal cancer (CRC):
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Breast cancer (BC):
A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Ovarian cancer (OC):
The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
Hepatocellular carcinoma (HCC):
A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.
Keratosis, seborrheic (KERSEB):
A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP):
A syndrome characterized by a spectrum of anomalies including primary megalencephaly, prenatal overgrowth, brain and body asymmetry, cutaneous vascular malformations, digital anomalies consisting of syndactyly with or without postaxial polydactyly, connective tissue dysplasia involving the skin, subcutaneous tissue, and joints, and cortical brain malformations, most distinctively polymicrogyria.
Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE):
A sporadically occurring, non-hereditary disorder characterized by asymmetric somatic hypertrophy and anomalies in multiple organs. It is defined by four main clinical findings: congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal/spinal abnormalities. The presence of truncal overgrowth and characteristic patterned macrodactyly at birth differentiates CLOVE from other syndromic forms of overgrowth.
Cowden syndrome 5 (CWS5):
A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid.
CLAPO syndrome (CLAPO):
A syndrome characterized by capillary malformation of the lower lip, lymphatic malformation of the face and neck, asymmetry of face and limbs and partial or generalised overgrowth.
Macrodactyly (MADAC):
A congenital anomaly characterized by fibrofatty tissue enlargement and bony overgrowth affecting the digits or the entire hand or foot.